Rebus Holdings, Inc. (RBSH)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -1.02 Million USD | -177.59% |
| 2021 | 1.61 Million USD | 134.9% |
| 2020 | -4.62 Million USD | -170.49% |
| 2019 | -1.71 Million USD | -14158.33% |
| 2018 | -12 Thousand USD | 99.89% |
| 2017 | -11.1 Million USD | -212.24% |
| 2016 | -3.55 Million USD | 39.6% |
| 2015 | -5.88 Million USD | 15.84% |
| 2014 | -6.99 Million USD | -31.91% |
| 2013 | -5.3 Million USD | 23.38% |
| 2012 | -6.92 Million USD | -21.1% |
| 2011 | -5.71 Million USD | -34.2% |
| 2010 | -4.25 Million USD | 17.05% |
| 2009 | -5.13 Million USD | -54.31% |
| 2008 | -3.32 Million USD | -381.23% |
| 2007 | -691.19 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -718 Thousand USD | -149.76% |
| 2023 Q2 | 43 Thousand USD | 105.99% |
| 2022 FY | -1.25 Million USD | -177.59% |
| 2022 Q1 | -1.02 Million USD | -2078.85% |
| 2022 Q3 | 758 Thousand USD | 131.26% |
| 2022 Q2 | -2.42 Million USD | -135.67% |
| 2022 Q4 | 1.44 Million USD | 90.37% |
| 2021 Q1 | -20.63 Million USD | -217.46% |
| 2021 Q2 | 17.15 Million USD | 183.14% |
| 2021 Q3 | 6.12 Million USD | -64.3% |
| 2021 Q4 | 52 Thousand USD | -99.15% |
| 2021 FY | 1.61 Million USD | 134.9% |
| 2020 Q3 | 2.1 Million USD | 279.23% |
| 2020 Q4 | -6.5 Million USD | -408.64% |
| 2020 FY | -4.62 Million USD | -170.49% |
| 2020 Q1 | -726 Thousand USD | -64.25% |
| 2020 Q2 | -1.17 Million USD | -61.85% |
| 2019 Q1 | -75 Thousand USD | -103.55% |
| 2019 Q4 | -442 Thousand USD | -204.99% |
| 2019 Q2 | -838 Thousand USD | -1017.33% |
| 2019 Q3 | 421 Thousand USD | 150.24% |
| 2019 FY | -1.71 Million USD | -14158.33% |
| 2018 Q1 | -256 Thousand USD | 95.31% |
| 2018 FY | -12 Thousand USD | 99.89% |
| 2018 Q4 | 2.11 Million USD | 179.03% |
| 2018 Q3 | -2.67 Million USD | -472.01% |
| 2018 Q2 | 718 Thousand USD | 380.47% |
| 2017 FY | -11.1 Million USD | -212.24% |
| 2017 Q4 | -5.45 Million USD | -23.2% |
| 2017 Q3 | -4.43 Million USD | -704.17% |
| 2017 Q2 | -551 Thousand USD | 16.39% |
| 2017 Q1 | -659 Thousand USD | 51.33% |
| 2016 Q2 | -490 Thousand USD | 0.0% |
| 2016 Q1 | -490 Thousand USD | 56.9% |
| 2016 FY | -3.55 Million USD | 39.6% |
| 2016 Q3 | -1.22 Million USD | -149.18% |
| 2016 Q4 | -1.35 Million USD | -10.89% |
| 2015 Q2 | -1.53 Million USD | 16.87% |
| 2015 FY | -5.88 Million USD | 15.84% |
| 2015 Q4 | -1.13 Million USD | 17.19% |
| 2015 Q3 | -1.37 Million USD | 10.38% |
| 2015 Q1 | -1.84 Million USD | -11.29% |
| 2014 Q2 | -1.6 Million USD | 17.27% |
| 2014 FY | -6.99 Million USD | -31.91% |
| 2014 Q3 | -1.79 Million USD | -11.71% |
| 2014 Q4 | -1.65 Million USD | 7.64% |
| 2014 Q1 | -1.94 Million USD | 5.64% |
| 2013 Q1 | -1.29 Million USD | -0.05% |
| 2013 FY | -5.3 Million USD | 23.38% |
| 2013 Q4 | -2.05 Million USD | -104.58% |
| 2013 Q3 | -1 Million USD | -6.46% |
| 2013 Q2 | -944 Thousand USD | 27.22% |
| 2012 FY | -6.92 Million USD | -21.1% |
| 2012 Q3 | -1.77 Million USD | -107.45% |
| 2012 Q4 | -1.29 Million USD | 26.94% |
| 2012 Q2 | -855.32 Thousand USD | 71.43% |
| 2012 Q1 | -2.99 Million USD | -55.14% |
| 2011 Q1 | -348.71 Thousand USD | 79.28% |
| 2011 Q2 | -1.69 Million USD | -386.42% |
| 2011 Q4 | -1.92 Million USD | -10.96% |
| 2011 FY | -5.71 Million USD | -34.2% |
| 2011 Q3 | -1.73 Million USD | -2.53% |
| 2010 Q3 | 290.94 Thousand USD | 141.8% |
| 2010 Q2 | -696.08 Thousand USD | 67.92% |
| 2010 Q4 | -1.68 Million USD | -678.33% |
| 2010 FY | -4.25 Million USD | 17.05% |
| 2010 Q1 | -2.17 Million USD | -122.21% |
| 2009 Q4 | -976.56 Thousand USD | 39.87% |
| 2009 Q2 | -974.59 Thousand USD | 37.43% |
| 2009 FY | -5.13 Million USD | -54.31% |
| 2009 Q1 | -1.55 Million USD | -16.64% |
| 2009 Q3 | -1.62 Million USD | -66.65% |
| 2008 Q2 | -508.54 Thousand USD | 3.54% |
| 2008 Q4 | -1.33 Million USD | -39.8% |
| 2008 Q3 | -955.18 Thousand USD | -87.83% |
| 2008 FY | -3.32 Million USD | -381.23% |
| 2008 Q1 | -527.19 Thousand USD | 0.0% |
| 2007 FY | -691.19 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 23.62% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 85.393% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 101.925% |
| Nascent Biotech, Inc. | -2.08 Million USD | 51.142% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 101.566% |
| Qrons Inc. | -789.34 Thousand USD | -29.221% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -61.289% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 98.371% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -145.5% |
| Skye Bioscience, Inc. | -37.64 Million USD | 97.29% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 98.639% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 84.489% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -273.077% |
| SQZ Biotechnologies Company | -79.46 Million USD | 98.716% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 64.735% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 43.972% |
| Mesoblast Limited | -87.95 Million USD | 98.84% |
| Marizyme, Inc. | -65.34 Million USD | 98.439% |
| Genus plc | 7.9 Million USD | 112.911% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 90.635% |
| Pharming Group N.V. | -10.54 Million USD | 90.33% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 52.991% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 72.508% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 88.467% |
| ContraFect Corporation | -65.15 Million USD | 98.434% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 79.124% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 40.954% |
| IMV Inc. | -36.48 Million USD | 97.204% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 87.344% |
| MultiCell Technologies, Inc. | -380.07 USD | -268271.616% |
| ONE Bio Corp. | 8.67 Million USD | 111.756% |
| Accustem Sciences Inc. | -3.74 Million USD | 72.774% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 98.027% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 19.503% |
| Q BioMed Inc. | -2.05 Million USD | 50.295% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 72.676% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 57.159% |
| Biomind Labs Inc. | -1.21 Million USD | 16.002% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 98.292% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 67.116% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 87.094% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 47.672% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -6710.897% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 93.573% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 82.466% |
| GB Sciences, Inc. | -1.36 Million USD | 25.092% |
| Alpha Cognition Inc. | -13.77 Million USD | 92.594% |
| HST Global, Inc. | -146.21 Thousand USD | -597.627% |
| CSL Limited | 2.64 Billion USD | 100.039% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 41.873% |
| Halberd Corporation | -79.67 Thousand USD | -1180.185% |
| Enzolytics Inc. | -2.17 Million USD | 53.143% |
| Agentix Corp. | -1.37 Million USD | 25.776% |
| Resverlogix Corp. | -3.61 Million USD | 71.745% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 67.838% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.654% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1140.816% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 114.73% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 74.327% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 66.294% |
| AVAX Technologies, Inc. | -6.41 Million USD | 84.096% |
| Zenith Capital Corp. | -10.59 Million USD | 90.374% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.932% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -4288.607% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 75.398% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -1587.607% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 49.13% |
| Kadimastem Ltd | -3.3 Million USD | 69.16% |
| Helix BioMedix, Inc. | -1.05 Million USD | 3.414% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 73.291% |
| BioStem Technologies, Inc. | -8.48 Million USD | 87.976% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -131.099% |
| LadRx Corporation | 400.44 Thousand USD | 354.718% |
| Cell Source, Inc. | -5.32 Million USD | 80.831% |
| Regen BioPharma, Inc. | 1.02 Million USD | 199.657% |
| Regen BioPharma, Inc. | 1.02 Million USD | 199.657% |
| NovAccess Global Inc. | -4.76 Million USD | 78.613% |
| Affymax, Inc. | -14.42 Million USD | 92.928% |
| Itoco Inc. | -1.86 Million USD | 45.425% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 77.04% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 38.886% |
| Mobile Lads Corp. | -2.26 Million USD | 54.933% |
| CytoDyn Inc. | -49.84 Million USD | 97.953% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -1190.6% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -347.119% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -8.334% |
| SYBLEU INC | -180.3 Thousand USD | -465.711% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 36.753% |
| International Stem Cell Corporation | -131 Thousand USD | -678.626% |
| Bioxytran, Inc. | -4.28 Million USD | 76.168% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -1779.422% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 59.688% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 97.878% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 51.75% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -30.621% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 67.803% |
| Neutra Corp. | -233.46 Thousand USD | -336.896% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 94.973% |
| PureTech Health plc | -65.69 Million USD | 98.447% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 95.204% |
| IXICO plc | -1.17 Million USD | 13.413% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 89.725% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 98.215% |
| CSL Limited | 2.64 Billion USD | 100.039% |
| Cellectis S.A. | -103.17 Million USD | 99.011% |